Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Gilenya for MS in Children ≥10 Years

FDA Web site; 2018 May 11

The US Food and Drug Administration (FDA) recently approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents aged ≥10 years. This is the first FDA approval of a drug to treat MS in pediatric patients. Gilenya was first approved by the FDA in 2010 to treat adults with relapsing MS. The FDA granted the approval of Gilenya to Novartis, which is headquartered in Basel, Switzerland.

Most people with MS experience their first symptoms, such as vision problems or muscle weakness, between the ages of 20 to 40. 2-5% of people with MS have symptom onset <18 years and estimates suggest that 8,000 to 10,000 children and adolescents in the US have MS.

Indications: Gilenya is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS) in patients ≥10 years.

Dosage/administration: Recommended dosage for adults and pediatric patients (≥10 years) weighing >40 kg: 0.5 mg orally once-daily, with or without food. Recommended dosage for pediatric patients (≥10 years) weighing ≤40 kg: 0.25 mg orally once-daily, with or without food. Additional information:

Adverse reactions: Most common adverse reactions (incidence ≥10% and >placebo): headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.


FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients. FDA Web site. May 11, 2018. Accessed May 18, 2018.

This Week's Must Reads

Impact of Infant Rotavirus Vaccination on All Ages, Clin Infect Dis; ePub 2018 Jul 18; Baker, et al

Strategies to Achieve Universal Flu Vaccination, Acad Pediatr; ePub 2018 Jul 18; Saville, et al

Parental Attitudes About Vaccination Exemptions, PLoS One; ePub 2018 Jun 14; Pottinger, Jacobs, et al

HPV Initiation by Sexual Orientation and Race, J Womens Heath; ePub 2018 Jun 29; Agénor, et al

Gender Disparity in Rhode Island for HPV Vaccine , Am J Public Health; ePub 2018 Jul 19; Thompson, et al

Must Reads in FDA Actions

FDA Approves System for Children with T1D, Medtronic plc news release; 2018 Jun 21

FDA Approves Oral Briviact for Pediatric Epilepsy, UCB news release; 2018 May 14

FDA Approves Otiprio for Swimmer’s Ear Infection, FirstWordPharma news release; 2018 Mar 2

New Approval for Treatment of Chagas Disease, FDA news release; 2017 Aug 29